SCHEMBL6802932

SCHEMBL6802932

N#CC(C(N)=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.44
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TNF P01375 1/20 0.40
S1PR3 Q99500 3/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
TSHR P16473 1/20 0.36
S1PR4 O95977 1/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
IDO2 Q6ZQW0 1/20 0.36
S1PR1 P21453 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5141561 0.85 MDM2 (0.42) S1PR3TSHRS1PR4IDO1S1PR1
SCHEMBL30141294 0.83 SLC6A3 (0.46) SLC6A3ALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL10478253 0.83 SLC6A3 (0.44) SLC6A3ALDH1A1TNFIDO1TDO2
SCHEMBL6802464 0.80 HDAC4 (0.44) ALDH1A1LMNAHTTSMN1; SMN2TSHR
SCHEMBL11811321 0.79 IDO1 (0.43) SLC6A3ALDH1A1S1PR3SLC6A2SLC6A4
SCHEMBL20767316 0.79 SLC6A3 (0.41) SLC6A3ALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL7200920 0.79 SLC6A3 (0.41) SLC6A3ALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL21296577 0.78 TNF (0.47) SLC6A3ALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL6802967 0.78 PARP1 (0.44) ALDH1A1HTTSMN1; SMN2
SCHEMBL7200003 0.78 S1PR4 (0.41) SLC6A3ALDH1A1LMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730671-B2 ENZYME INHIBITOR TREATING AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-05-04 US disclosed
US-20030158406-A1 Compounds useful as reversible inhibitors of cathepsin S BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-08-21 US disclosed
US-6608057-B2 Compounds useful as reversible inhibitors of cathepsin S BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-08-19 US disclosed
US-20020091259-A1 Compounds useful as reversible inhibitors of cathepsin S CYWIN CHARLES L (US) 2002-07-11 US disclosed
US-6395897-B1 DRUGS FOR ENZYME INHIBITORS ANTICOAGULANTS AND TREATMENT OF AUTOIMMUNE DISEASE BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2002-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091259-A1 Compounds useful as reversible inhibitors of cathepsin S CTSS, CTSB, CTSV SLC6A3 4275/4885ALDH1A1 1591/4885LMNA 3225/4885
US-20030158406-A1 Compounds useful as reversible inhibitors of cathepsin S CTSS, CTSB, CTSV SLC6A3 4275/4885ALDH1A1 1591/4885LMNA 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.